The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


US FTC approves Teva?s $40.5bn deal for Allergan?s generics business.....           US FTC approves Teva?s $40.5bn deal for Allergan?s generics business.....           Neurovance?s centanafadine ADHD drug meets main goals in phase 2b trial.....           Neurovance?s centanafadine ADHD drug meets main goals in phase 2b trial.....           TauRx's LMTX Alzheimer's drug fails to meet co-primary endpoints in phase 3 trial.....           TauRx's LMTX Alzheimer's drug fails to meet co-primary endpoints in phase 3 trial.....           Kite Pharma announces exclusive license with NIH for anti-CD19 CAR product candidate.....           Kite Pharma announces exclusive license with NIH for anti-CD19 CAR product candidate.....           Vectura initiates legal proceedings against GlaxoSmithKline.....           Vectura initiates legal proceedings against GlaxoSmithKline.....           Almirall, Sun Pharma sign license deal to develop tildrakizumab for psoriasis in Europe.....           Almirall, Sun Pharma sign license deal to develop tildrakizumab for psoriasis in Europe.....           Hemispherx signs deal with Avrio Biopharmaceuticals for accelerated production of Ampligen.....           Hemispherx signs deal with Avrio Biopharmaceuticals for accelerated production of Ampligen.....           Eisai doses first patient in phase 1b/2 clinical trial of eribulin in combination with PEGPH20.....           Eisai doses first patient in phase 1b/2 clinical trial of eribulin in combination with PEGPH20.....           GlaxoSmithKline gives U.K. some post-Brexit love with $360 million in plant investments.....           With strong Q2, GSK chief Witty sees solid growth platform for his as-yet-unnamed replacement.....           Amgen jacks up its full-year guidance as Q2 revenue, earnings beat the Street.....           Bristol-Myers Squibb, Janssen collaborate on lung cancer treatment.....           Bristol-Myers Squibb, Janssen collaborate on lung cancer treatment.....           Quantum Pharma launches Mucodis Rectal Gel.....           Quantum Pharma launches Mucodis Rectal Gel.....           Espada acquires GlyDerm line of skin care products from Lautus Pharmaceuticals.....           Espada acquires GlyDerm line of skin care products from Lautus Pharmaceuticals.....           LSK BioPharma announces successful outcome from End-of-Phase 2 meeting with FDA for apatinib.....           LSK BioPharma announces successful outcome from End-of-Phase 2 meeting with FDA for apatinib.....           Trek Therapeutics acquires two antiviral inhibitors from Vertex Pharmaceuticals.....           Trek Therapeutics acquires two antiviral inhibitors from Vertex Pharmaceuticals.....           Recro Pharma?s IV Meloxicam achieves primary endpoint in first of two pivotal trials.....           Recro Pharma?s IV Meloxicam achieves primary endpoint in first of two pivotal trials.....           Bristol-Myers' Opdivo front and center in yet another cancer-fighting partnership, this time with Janssen.....           Philly host committee taps Digitas Health for DNC digital and social media work.....           Just Biotherapeutics secures $14M series A2 funding.....           Eiger doses first patient in phase 2 study of Ubenimex in secondary lymphedema.....           Just Biotherapeutics secures $14M series A2 funding.....           FDA lifts clinical hold on CGF166.....           FDA lifts clinical hold on CGF166.....           Tricida raises $55m for kidney disease treatment.....           Tricida raises $55m for kidney disease treatment.....           Merck's Ebola Zaire vaccine gets accelerated review designations in US and Europe.....           Merck's Ebola Zaire vaccine gets accelerated review designations in US and Europe.....           Fresh off a 9% quarterly sales hike, Lilly sees new launches driving solid growth through 2020.....           Gilead's new launch Genvoya racks up big script growth in fastest HIV rollout since Atripla.....           Stada activist hits back with its own board picks in fierce duel for company control.....           Bristol-Myers' Opdivo front-and-center in yet another cancer-fighting team-up, this time with Janssen.....           Rebel Depomed investor adds former J&J, Abbott execs to its proposed board slate.....           J&J sets sights on bigger Darzalex market with FDA 'breakthrough' in second-line myeloma.....           AbbVie, Bristol-Myers Squibb partner on combo treatment for lung cancer.....           Vtesse secures $17m in additional Series A funding.....           UPDATED: Analysts press for M&A as Gilead?s high-flying hep C franchise comes down to earth.....           European CHMP recommends Shire?s Onivyde to treat metastatic adenocarcinoma.....           FDA raises concerns over manufacturing practice of Valeant?s new ophthalmic solution.....           Bristol-Myers to combo Opdivo, Yervoy with AbbVie's Rova-T in next-gen cancer cocktail trials.....           Dem VP pick Kaine jetted to Aspen on pharma's dime, and the $12K gift from Teva's Barr is raising eyebrows.....           Boehringer calls it quits on Gilotrif expansion effort in head and neck cancer.....           Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis.....           Merck's Ebola vaccine grabs FDA, EMA milestones in push toward licensure.....           Gilead?s high-flying hep C franchise comes down to earth, forcing a cut to 2016 guidance.....           Valeant's Relistor a future blockbuster? With AZ in the game, analysts aren't buying it.....           Bayer, J&J land top 10 spots in brand power ranking.....           Takeda launches new DTC campaign for renamed depression med Trintellix.....           FDA Grants QIDP to Morphochem?s intravenous antibacterial to treat C. difficile infections.....           European CHMP adopts positive opinion on Gilead?s Type II variation application for Truvada.....           Chugai, Galderma sign license deal for nemolizumab.....           Gilead?s Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) meets primary objective in two phase 3b studies.....           Synaffix achieves improved therapeutic index compared to both FDA-approved ADCs.....           Citron Pharma launches Rosuvastatin calcium tablets.....           Puma submits NDA for PB272 to FDA for extended adjuvant treatment of HER2-Positive early stage breast cancer.....           Takeda explores $1B-plus sale of chemicals stake: Bloomberg.....           Valeant, working to rehab R&D image, gets FDA snub on potential blockbuster.....           AZ frustrated with Tagrisso NICE delay, calls for reform.....           BMS' Opdivo, Amgen's Repatha first on Japan's list for new price restrictions.....           AstraZeneca?s Zavicefta meets main goals in phase III trial to treat hospital-acquired pneumonia.....           Scancell appoints Eurogentec SCIB1 material manufacturer.....           Chugai, Galderma sign license deal for nemolizumab.....           Transgene to continue phase 1/1b study with TG1050 in Chronic Hepatitis B patients.....           Merck provides regulatory update on bezlotoxumab biologics licensing application.....           Amgen and Allergan study finds biosimilar comparable to Roche?s Herceptin breast cancer drug.....           InflaRx raises $34m for phase II development of IFX-1 anti-complement C5a antibody.....           EMA grants orphan drug designation to XOMA 358 to treat congenital hyperinsulinism.....           PeptiDream licenses PDPS technology to Genentech.....           West-Ward Pharmaceuticals launches generic Xeloda tablets 150 mg and 500 mg in US.....           Sapience Therapeutics signs license deal with Columbia University for novel cancer treatment.....           Synthorx raises $10m to develop and scale novel protein therapeutics.....           FDA accepts ApeX Therapeutics? IND for clinical testing of APX3330 in pancreatic cancer.....           In a warning sign for pharma, ex-J&J execs are convicted in off-label marketing case.....           Shire acquires stake in Chronos Therapeutics.....           ProQR secures FDA fast track designation for QR-010 to treat Cystic Fibrosis.....           AZ's FDA-rejected diabetes combo grabs first-to-market status in Europe.....           Pfizer's multidose Prevenar 13 wins WHO backing; early 2017 launch planned.....           Now cancer-free after Keytruda combo, Poison drummer Rikki Rockett ready to spread the word.....           Novartis CEO predicts drug pricing overhaul in U.S. after the election, whoever wins.....           Gilead greed protests continue at AIDS conference in wake of tax-cutting report.....           AZ's FDA-rejected diabetes combo grabs first-to-market status in Europe.....           Pfizer's multidose Prevenar 13 wins WHO backing; early 2017 launch planned.....           Now cancer-free after Keytruda combo, Poison drummer Rikki Rockett ready to spread the word.....           Novartis CEO predicts drug pricing overhaul in U.S. after the election, whoever wins.....           Gilead greed protests continue at AIDS conference in wake of tax-cutting report.....           European Commission approves AstraZeneca?s Qtern to treat type 2 diabetes.....           Vernalis achieves milestone in oncology drug discovery collaboration with Servier.....           VBI Vaccines applies eVLP Platform to develop novel vaccine candidate to prevent Zika virus.....           Stellar Biotechnologies, Neovacs establish new company in France.....           FDA approves expanded label for NAMZARIC to treat moderate to severe Alzheimer's disease.....           FDA approves Relistor tablets to treat OIC in chronic non-cancer pain adults.....           MilliporeSigma starts work on $115m life science campus in Massachusetts.....           UPDATED: Novartis warns profits may slip as it bets an extra $200M on Entresto.....           UPDATED: J&J hikes forecast as standouts Imbruvica, Xarelto crank up pharma growth.....           Merck KGaA to build $115M Boston hub, aiming for a higher profile in biopharma hotspot.....           FDA rejects Sandoz's Neulasta copy, giving Amgen a break from the biosim onslaught.....           FDA panel unanimously backs Valeant's suicide-linked psoriasis med, but serious competition awaits.....           UPDATED: Novartis warns profits may slip as it bets an extra $200M on Entresto.....           UPDATED: J&J hikes forecast as standouts Imbruvica, Xarelto crank up pharma growth.....           Merck KGaA to build $115M Boston hub, aiming for a higher profile in biopharma hotspot.....           FDA rejects Sandoz's Neulasta copy, giving Amgen a break from the biosim onslaught.....           FDA panel unanimously backs Valeant's suicide-linked psoriasis med, but serious competition awaits.....           FDA and EMA accept Bristol-Myers? filing for expanded Opdivo indications.....           Poxel closes €26.5m capital increase.....           Advanced Proteome formulates strategic plan featuring novel antibody program.....           Perrigo wins FDA approval fo romeprazole and sodium bicarbonate capsules, 20mg/1100mg.....           Eiger doses first patient in phase 2 LIBERTY study of ubenimex in pulmonary arterial hypertension.....           Tiziana acquires bio-repository from Shardna.....           Samsung Bioepis' Humira biosimilar application accepted for review in Europe.....           Novartis warns profits may decline on Gleevec copies, spending boost for Entresto, Cosentyx.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Call for applicants for two Board vacancies

Two of the current Board members will retire from the Board at the AGM in September and so the APS is seeking applications from individuals interested in becoming Board members.

The APS Board consists of 8 people, who are registered as Directors of APS at Companies House. This means that becoming a member of the Board brings legal obligations related to the management of APS. Board members are expected to attend 4 face to face meetings a year, two of which are one-day meetings usually held in London, and two are two-day meetings held at a suitable location (recently Burleigh Court, Loughborough).

Board members should have a broad perspective across the pharmaceutical sciences and should have some experience of managing timelines and budgets and of working in a team environment. Board members act as a team to manage the business of APS, and are not representatives of their employer. Within their capacity as an APS Board member they are expected to always act in the best interests of APS.

Enthusiasm and commitment are the main skills needed but experience in financial management and/or IT skills (use of social media, website management etc) would be particularly useful to expand the range of expertise on the Board.

Individuals wishing to be considered for a role should send a 1-page CV and a short statement describing the skills they would bring to the Board and their goals and objectives if appointed. Applicants will be reviewed by an Appointments Panel consisting of two Board members and three Advisory Board members. The Panel will make a recommendation to the Board which will make the final appointment. The new Board members will be presented to the AGM in September for ratification.

Please send applications to the APS Secretariat (info@apsgb.org) by 1 August 2016.

Latest News
APS Symposium on the Digital Design of Drug Products
MONDAY, 13 JUNE 2016
APS Symposium on the Digital Design of Drug Products 1st July 2016, University of Leeds. The design of new medicinal products is a risky and lengthy process. Current approaches utilise a make and test philosophy to understand processing risk. This requires large amounts of materials and knowledge is often limited by short development timelines and availability of input materials. Hence formulations are often developed that merely accommodate variability in drug substance rather than making it an opportunity and thus a heavily over-engineered formulation and process can be produced. The area of digital design has the opportunity to revolutionise the development and manufacturing of new medicines by utilising both mechanistic and big data approaches to produce holistic models for our processes. This will allow optimal processes and materials to be produced which will permit more rapid development and result in improved robustness of manufacturing processes. This event brings together the concept of materials engineering with state of the art knowledge around modelling of materials and processes. It will provide information around initiatives in the pharmaceutical arena where data sharing is helping to produce better guidelines for processes. An opportunity will also be provided to learn about the recently £24M funded ADDoPT (Advanced Digital Design on Pharmaceutical Therapeutics) project which is aimed to provide new tools to the industry in the area of materials manufacture and processing. The meeting is organised by the Academy of Pharmaceutical Sciences but is kindly facilitated by BACG and CGOM. It is a must attend for scientists and leaders in the pharmaceutical development and manufacturing sector as well as an opportunity for other manufacturing industries to learn about new developments that could be adopted on their processes. For more details please contact C.Y.Ma@Leeds.ac.uk Registration for the APS Symposium is now open. Register here: http://www.crystalgrowth2016.co.uk/aps/. On Thursday evening, before the APS Symposium, Tommy Dolan will be giving an evening lecture on “The Future of Medicines Manufacture: Towards Digital Design”. The Conference dinner will also be taking place on Thursday evening. Expressions of interest for the evening lecture series will be opened closer to the event but the conference dinner and accommodation at the University of Leeds can be booked in addition to your APS registration. Friday 1st July – APS Symposium 09:30 10:00 Registration & Refreshments 10:00 10:05 Welcome – Richard Storey, AstraZeneca/APS Treasurer 10:05 10:45 Keynote #1 – Calvin Sun, University of Minnesota The Materials Science Tetrahedron – The Academic Vision Invited modelling presentations 10:45 11:15 Mojtaba Ghadiri, University of Leeds Particle breakage modelling 11:15 11:45 Jim Litster, University of Sheffield Wet granulation experimental and modelling 11:45 12:15 James Elliott, University of Cambridge Compaction modelling (and DEM solution on DEM modelling) 12:15 13:20 Lunch 13:20 13:50 Industrial Perspective – Kendall Pitt, GlaxoSmithKline The MCS – The Drive From Industry 13:50 14:30 Keynote #2 – Amrit Paudel, Research Centre for Pharmaceutical Engineering Stability by Design 14:30 14:50 Refreshment Break 14:50 15:20 Richard Storey, AstraZeneca Towards the Perfect Particle: What are the important design attributes? 15:20 16:00 Costas Pantelides, Process Systems Enterprise ADDoPT Vision: System-based Pharmaceutics 16:00 16:30 Summary and Close
APS and RPS Awards Announcement
THURSDAY, 12 MAY 2016
APS Innovative Science Award Lecture 2016. The Academy of Pharmaceutical Sciences present the Innovative Science Award and invite pharmaceutical scientists to submit an application. Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the Innovative Science Award Lecture on their work at APS PharmSci 2016. Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 500 words, focussing on its importance to the pharmaceutical industry. Entries should be submitted via email to Alan Ramsay at info@apsgb.org including ‘Innovative Science Award 2016’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel. Closing Date for Entries 31st May 2016. . 2016 Royal Pharmaceutical Society Science Award Applications are invited for the 2016 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the 7th Academy of Pharmaceutical Sciences International PharmSci Conference on the 7th September 2016. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2016, applicants must have a proven record of independent research and published work that shows outstanding promise. Applicants are invited to submit the following details by 20th May 2016:. Full CV detailing personal information, past and present appointments, research responsibilities and published work. List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations. Details of research grants awarded and the candidate’s role. Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards. A brief resume of two pages should also be submitted with the CV, indicating discoveries made. Please note copies of publications are not required. Applications should be made by 20th May 2016 preferably by email (jayne.lawrence@rpharms.com) or by post to: Jayne Lawrence, Chief Science Advisor Royal Pharmaceutical Society 66 East Smithfield, London, E1W 1AW.
APS Manufacturing Classification System
TUESDAY, 10 MAY 2016
Be Part of a Successful Global Partnership –APS Manufacturing Classification System . 'Pharmaceutical Sciences: Improving World Health'. Monday 5th – Wednesday 7th September 2016 at the Technology and Innovation Centre, University of Strathclyde, Glasgow. A roundtable session has been organised on Tuesday 6th September at 12.15-13.30, co-chaired by Kendal Pitt (GSK) and Gavin Reynolds (AstraZeneca) giving you the opportunity to input into the Manufacturing Classification System (MCS) and its implementation.. The MCS is a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the Active Pharmaceutical Ingredient (API) and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing based on "ideal" ranges for API physical properties and therefore indicate how robust a manufacturing process is likely to be in relation to those properties.. This represents a very successful APS-driven Industry collaboration which has already resulted in a publication entitled “‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms”. This was the most downloaded article in Pharmaceutical Development & Technology of 2015 and the cross-industry authors have been commended for their contribution to Pharmaceutical Development & Technology.. For more information and to register for the conference, go tohttp://www.ukpharmsci.org/register/default.asp on or before 31st July 2016 to take advantage of the Early Bird Rates for the conference..
APS Alternatives to Antibiotics Meeting
THURSDAY, 21 APRIL 2016
APS Alternatives to Antibiotics Meeting Thursday 16th June 2016 Burleigh Court - Loughborough. Keynote speaker- Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics. This one day meeting focussing on exploration of possible opportunities for alternative approaches to traditional antibacterial compounds as potential clinical approaches for treating infectious diseases will be held on Thursday 16th June 2016 at Burleigh Court, Loughborough, Leicestershire (http://www.burleigh-court.co.uk/) organised by the APS Microbiology and Anti-infectives Focus Group.. Background to the Meeting:. The withdrawal last Century by the majority of Big Pharma from antibiotic research and development programmes, coupled with other aspects such as a lack of global stewardship over use, has led to the current situation where resistance has left a critical lack of efficacious compounds. The pipeline for development of new antimicrobial agents is critically stagnant and the time to seriously examine viable alternatives for tackling multi-drug resistant pathogens has arrived. The purpose for this meeting will be to allow delegates to hear presentations on a series of alternative approaches including bacteriophage and endolysin therapy, probiotics, antibody technology and immune intervention, which collectively represent the most likely of the alternative approaches to yield genuine clinical impact. Our speakers will highlight the current knowledge base of development in the field in pursuit of discovery of alternatives to antibiotics.. The purpose and aims of the APSGB Microbiology and Anti-Infectives Focus Group is to provide a forum for the discussion of all aspects of microbiology and anti-infectives research and development in the pharmaceutical industry and academia, to underpin the importance of microbiology to the pharmaceutical sciences and innovation, and to provide continuing education, resources and a voice for pharmaceutical scientists in the challenging area of antimicrobials development.. Meeting Format: . We are very pleased to offer a stimulating one day programme of presentations from high profile speakers who are leading experts in their particular fields of research into alternative approaches to traditional small molecule antibiotics, and include representatives of academia, biotechnology SMEs and the pharmaceutical industry.. The Keynote lecture will be delivered by Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics, which was published in Lancet Infectious Diseases in January 2016 (http://dx.doi.org/10.1016/S1473-3099(15)00466-1). Dr Czeplewski is Founder and Director of Chemical Biology Ventures in and Abgentis, is an international opinion leader and successful scientist entrepreneur in the antibacterial R&D sector. He is currently a champion of the Alternatives to Antibiotics pioneering approaches for treatment of infectious diseases and he will be speaking specifically on this topic.. For more information and registrations, please visit us online at:. http://www.apsgb.co.uk/events/default.asp.
Follow us
 
Upcoming Events
APS PharmaFocus Day
8 August 2016
MIBio 2016: Stability of biopharmaceuticals
September 2016
APS 7th International PharmSci Conference 2016
5 - 7 September 2016
APS Delivery of High Dose Inhaled Drugs
October 2016
APS Basic Biopharmaceutics Workshop
12 October 2016
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.